Skip to content

Coherus Oncology, Inc.

CHRS· Nasdaqxbrl foundCIK 1512762

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -7.54%
Market cap
$83.36M
154.54M shares
Filings
923
$14.27M
Q3 2026+59.8% FY25 yoy
-$39.33M
Q3 2026+489.4% FY25 yoy
-$33.65M
Q3 2026N/M FY25 yoy
-$175.17M
FY 2023derivedN/M FY23 yoy
-$0.25
Q3 2026+472.0% FY25 yoy
$53.49M
Q3 2026−29.5% FY25 yoy
$83.36M
—
1.6×
3.3×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$0.539460.34%$0.8206past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$42.17MFY 2025
$475.82M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$42,172,000reported
FY 20242024-12-31$26,389,000 revisedreported
FY 20232023-12-31$257,244,000reported
FY 20222022-12-31$211,042,000reported
FY 20212021-12-31$326,551,000reported
FY 20202020-12-31$475,824,000reported
FY 20192019-12-31$356,071,000reported
FY 20182018-12-31$0reported
FY 20172017-12-31$1,556,000reported
FY 20162016-12-31$189,476,000 revisedreported
FY 20152015-12-31$30,041,000reported
FY 20142014-12-31$31,106,000reported

Capital returns

Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2014—$2.00K$2.00K—33.32M sh+588.8%—

Segments

Products
Revenue by Products, FY2019 to FY2025FY2019FY2020UDENYCA · FY2020 · $475.82MFY2021Other revenue · FY2021 · $42.00KUDENYCA · FY2021 · $326.51MFY2022Other revenue · FY2022 · $282.00KCIMERLI · FY2022 · $6.95MUDENYCA · FY2022 · $203.81MFY2023Toripalimab · FY2023 · $554.00KOther revenue · FY2023 · $664.00KCIMERLI · FY2023 · $125.39MUDENYCA · FY2023 · $127.06MYUSIMRY · FY2023 · $3.57MFY2024Toripalimab · FY2024 · $19.13MOther revenue · FY2024 · $7.26MCIMERLI · FY2024 · $27.08MUDENYCA · FY2024 · $205.95MYUSIMRY · FY2024 · $7.54MFY2025Toripalimab · FY2025 · $40.84MOther revenue · FY2025 · $1.34M
LineFY2025ShareChange
Toripalimab$40.84M97%+113.5%
Other revenue$1.34M3.2%−81.6%
CIMERLI———
UDENYCA———
YUSIMRY———
Total$42.17M

From the 10-K filed Mar 9, 2026CHRS

Biological products, except diagnostic substances

Coherus Oncology, Inc. is the 45th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Coherus Oncology, Inc. · CIK 1512762 · Engraved from SEC EDGAR